See more : GRAIL, Inc. Common Stock (GRALV) Income Statement Analysis – Financial Results
Complete financial analysis of Ind-Swift Limited (INDSWFTLTD.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ind-Swift Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Fortune Electric Co., Ltd. (1519.TW) Income Statement Analysis – Financial Results
- THC Therapeutics, Inc. (THCT) Income Statement Analysis – Financial Results
- Fintech Ecosystem Development Corp. (FEXD) Income Statement Analysis – Financial Results
- Federal National Mortgage Association (FNMAN) Income Statement Analysis – Financial Results
- Valeo Pharma Inc. (VPHIF) Income Statement Analysis – Financial Results
Ind-Swift Limited (INDSWFTLTD.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.indswiftltd.com
About Ind-Swift Limited
Ind-Swift Limited manufactures and sells pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrheal, anti-malarial, anti-depressants, cardiology, diabetology, neurology, and oncology. The company also provides contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.02B | 4.11B | 3.98B | 3.56B | 3.30B | 2.89B | 2.70B | 2.63B | 3.04B | 4.17B | 5.70B | 3.93B | 8.99B | 6.89B | 5.94B | 5.19B | 3.80B |
| Cost of Revenue | 2.85B | 2.18B | 2.36B | 2.10B | 2.12B | 1.84B | 1.79B | 1.64B | 2.51B | 3.93B | 4.86B | 3.05B | 6.96B | 5.37B | 4.53B | 3.88B | 2.84B |
| Gross Profit | 2.17B | 1.93B | 1.62B | 1.46B | 1.18B | 1.05B | 908.27M | 987.38M | 530.19M | 238.24M | 839.49M | 878.77M | 2.03B | 1.53B | 1.40B | 1.31B | 957.85M |
| Gross Profit Ratio | 43.24% | 46.94% | 40.63% | 41.09% | 35.77% | 36.30% | 33.66% | 37.54% | 17.42% | 5.71% | 14.73% | 22.35% | 22.60% | 22.13% | 23.62% | 25.24% | 25.22% |
| Research & Development | 121.94M | 95.90M | 52.42M | 39.01M | 34.31M | 29.58M | 31.85M | 4.08M | 5.55M | 5.21M | 7.16M | 4.78M | 5.25M | 7.31M | 7.83M | 0.00 | 0.00 |
| General & Administrative | 786.09M | 169.73M | 135.11M | 103.38M | 130.26M | 114.96M | 108.38M | 11.85M | 12.90M | 218.50M | 213.26M | 211.32M | 250.97M | 212.16M | 191.04M | 174.99M | 134.09M |
| Selling & Marketing | 38.54M | 281.53M | 305.91M | 272.95M | 214.77M | 184.68M | 150.76M | 26.77M | 30.51M | 203.06M | 385.50M | 375.84M | 388.24M | 298.44M | 260.12M | 316.36M | 268.61M |
| SG&A | 824.63M | 451.26M | 441.02M | 376.33M | 345.03M | 299.64M | 259.15M | 38.62M | 43.42M | 421.56M | 598.76M | 587.16M | 639.21M | 510.60M | 451.16M | 491.35M | 402.70M |
| Other Expenses | 0.00 | 118.54M | 20.29M | 27.05M | 33.42M | 7.59M | 718.31M | 2.12B | 2.18B | 769.72M | 681.93M | 581.51M | 221.99M | 194.52M | 170.08M | 122.22M | 80.47M |
| Operating Expenses | 946.57M | 1.80B | 1.31B | 1.28B | 1.16B | 1.14B | 1.01B | 2.17B | 2.23B | 1.20B | 1.29B | 1.17B | 866.45M | 712.44M | 629.07M | 613.57M | 483.16M |
| Cost & Expenses | 3.80B | 3.98B | 3.67B | 3.38B | 3.28B | 2.98B | 2.80B | 3.81B | 4.74B | 5.13B | 6.15B | 4.23B | 7.82B | 6.08B | 5.16B | 4.50B | 3.32B |
| Interest Income | 19.43M | 7.73M | 10.64M | 18.15M | 10.12M | 2.85M | 1.35M | 1.49M | 1.66M | 2.04M | 96.04M | 50.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 629.36M | 597.62M | 559.26M | 514.50M | 346.66M | 34.79M | 111.27M | 149.52M | 212.17M | 361.43M | 918.50M | 1.04B | 716.41M | 429.92M | 368.11M | 311.99M | 188.30M |
| Depreciation & Amortization | 271.07M | 286.68M | 320.73M | 327.03M | 335.94M | 339.73M | 346.31M | 357.32M | 363.52M | 393.63M | 262.64M | 163.82M | 155.14M | 121.50M | 94.75M | 58.51M | 33.84M |
| EBITDA | 1.07B | 1.14B | 618.21M | 469.62M | 521.20M | 174.02M | -72.83M | -3.12B | -1.44B | -682.45M | -160.57M | -109.86M | 1.32B | 934.64M | 867.67M | 755.48M | 508.53M |
| EBITDA Ratio | 21.20% | 13.11% | 17.34% | 16.99% | 13.89% | 9.28% | 10.65% | -31.67% | -43.09% | -14.39% | -1.09% | -0.23% | 14.69% | 13.56% | 14.62% | 14.55% | 13.39% |
| Operating Income | 1.23B | 160.17M | 297.48M | 142.59M | 27.77M | -165.71M | -58.94M | -1.19B | -1.67B | -994.04M | -324.87M | -172.71M | 1.17B | 813.14M | 773.07M | 696.97M | 474.69M |
| Operating Income Ratio | 24.40% | 3.90% | 7.48% | 4.00% | 0.84% | -5.73% | -2.18% | -45.25% | -55.03% | -23.83% | -5.70% | -4.39% | 12.96% | 11.79% | 13.02% | 13.42% | 12.50% |
| Total Other Income/Expenses | -1.06B | -825.47M | -1.36B | -374.53M | -1.03B | -658.29M | -426.02M | -2.53B | -64.63M | -515.59M | -957.60M | -1.30B | -716.41M | -429.92M | -368.26M | -311.99M | -188.30M |
| Income Before Tax | 164.64M | 260.37M | -196.02M | -294.93M | -166.61M | 57.71M | -533.77M | -3.63B | -2.00B | -1.47B | -1.24B | -1.21B | 448.09M | 383.22M | 404.81M | 384.98M | 286.39M |
| Income Before Tax Ratio | 3.28% | 6.34% | -4.93% | -8.28% | -5.06% | 2.00% | -19.78% | -137.96% | -65.64% | -35.32% | -21.82% | -30.76% | 4.99% | 5.56% | 6.82% | 7.41% | 7.54% |
| Income Tax Expense | 22.32M | 92.03M | 4.18M | 3.23M | 24.60M | 118.52M | 7.51M | 8.94M | 1.75M | -22.29M | -87.74M | -96.54M | 13.57M | 16.07M | 27.43M | 72.53M | 77.87M |
| Net Income | 142.31M | 260.37M | -200.20M | -298.16M | -191.21M | 57.71M | -504.30M | -3.72B | -2.00B | -1.45B | -1.16B | -1.11B | 434.52M | 367.15M | 377.38M | 312.46M | 208.52M |
| Net Income Ratio | 2.83% | 6.34% | -5.03% | -8.37% | -5.80% | 2.00% | -18.69% | -141.51% | -65.70% | -34.79% | -20.28% | -28.31% | 4.83% | 5.33% | 6.36% | 6.02% | 5.49% |
| EPS | 2.63 | 4.81 | -3.70 | -5.50 | -3.53 | 1.07 | -9.31 | -68.73 | -39.71 | -28.83 | -24.49 | -24.10 | 10.30 | 9.88 | 10.19 | 8.43 | 5.63 |
| EPS Diluted | 2.63 | 4.81 | -3.70 | -5.50 | -3.53 | 1.07 | -9.31 | -68.73 | -39.71 | -28.83 | -23.94 | -24.10 | 10.30 | 9.70 | 10.19 | 8.43 | 5.63 |
| Weighted Avg Shares Out | 54.11M | 54.16M | 54.16M | 54.16M | 54.16M | 54.16M | 54.16M | 54.16M | 50.35M | 50.34M | 47.18M | 46.18M | 42.18M | 37.18M | 37.05M | 37.05M | 37.05M |
| Weighted Avg Shares Out (Dil) | 54.16M | 54.16M | 54.16M | 54.16M | 54.16M | 54.16M | 54.16M | 54.16M | 50.35M | 50.35M | 48.27M | 46.18M | 42.18M | 37.18M | 37.05M | 37.05M | 37.05M |
Source: https://incomestatements.info
Category: Stock Reports